Axsome Therapeutics Inc (AXSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 4:15 PM ET
Axsome Therapeutics Inc (AXSM) Stock Chart
Axsome Therapeutics (AXSM) has a latest price of $135.95 on Nov 17, 2026, 47.7% below its 52-week high of $260.19. Its price fell 2.7% over the past 12 months. The month-end price rose 2,055.7% over the 10 years through Oct 2026, a compound annual rate of 35.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $244.77 in Jun 2026 and its lowest $2.45 in Mar 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AXSM with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AXSM.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 37.7%, and over 6 months it fell 40.0%. The month-end price rose 131.9% over the 3 years through Oct 2026, a compound annual rate of 32.4%.
| Period | Change |
|---|---|
| 1 month | -12.7% |
| 3 months | -37.7% |
| 6 months | -40.0% |
| 12 months | -2.7% |
| 12 months, with dividends | -2.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +131.9% | +32.4% |
| 5 years | +275.1% | +30.3% |
| 10 years | +2,055.7% | +35.9% |
Price by Year
Its best calendar year was 2019, when the price rose 3,565.2%, and its weakest was 2021, when it fell 53.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $144.43 | -20.9% |
| 2025 | $182.64 | +115.9% |
| 2024 | $84.61 | +6.3% |
| 2023 | $79.59 | +3.2% |
| 2022 | $77.13 | +104.2% |
| 2021 | $37.78 | -53.6% |
| 2020 | $81.47 | -21.2% |
| 2019 | $103.36 | +3,565.2% |
| 2018 | $2.82 | -49.6% |
| 2017 | $5.60 | -17.0% |
Trading Range
The price is 19.4% below its 50-day average of $168.62 and 30.8% below its 200-day average of $196.56.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $135.95 | |
| 52-week high | $260.19 | -47.7% |
| 52-week low | $123.00 | +10.5% |
| 50-day average | $168.62 | -19.4% |
| 200-day average | $196.56 | -30.8% |
Price Risk
Over 3 years, its largest fall from a peak was 49.1%.
| Measure | Value |
|---|---|
| 1-year beta | 0.72 |
| Largest fall, 1 year | -49.1% |
| Largest fall, 3 years | -49.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AXSM
What is AXSM's 1-year price change?
Axsome Therapeutics's price fell 2.7% over the past 12 months. With dividends included, the 12-month total return was -2.7%.
What is AXSM's 5-year price change?
Axsome Therapeutics's month-end price rose 275.1% over the 5 years through Oct 2026, a compound annual rate of 30.3%. These figures leave out dividends.
What is AXSM's 52-week high and low?
Axsome Therapeutics's 52-week high is $260.19 and its 52-week low is $123.00. Its latest price of $135.95 on Nov 17, 2026 is 47.7% below the high.
What is AXSM's beta?
Axsome Therapeutics's 1-year beta against the S&P 500 is 0.72, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 49.1%.
Is the AXSM chart free?
Yes. Advanced Charting for AXSM is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AXSM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors